{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:37:19Z","timestamp":1785253039704,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd015443","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000}}],"reference-count":143,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015443.pub2","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T06:48:22Z","timestamp":1725950902000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis"],"prefix":"10.1002","volume":"2025","author":[{"given":"Ben","family":"Ridley","sequence":"additional","affiliation":[{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna; Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia M","family":"Minozzi","sequence":"additional","affiliation":[{"name":"Department of Epidemiology; Lazio Regional Health Service; Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marien","family":"Gonzalez-Lorenzo","sequence":"additional","affiliation":[{"name":"Laboratorio di Metodologia delle revisioni sistematiche e produzione di Linee Guida; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Del Giovane","sequence":"additional","affiliation":[{"name":"Institute of Primary Health Care (BIHAM); Bern Switzerland"},{"name":"Department of Medical and Surgical Sciences; University of Modena and Reggio Emilia; Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Piggott","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact; McMaster University; Hamilton, Ontario Canada"},{"name":"Department of Family Medicine; Queens University; Kingston, Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Filippini","sequence":"additional","affiliation":[{"name":"Scientific Director\u2019s Office; Fondazione IRCCS, Istituto Neurologico Carlo Besta; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Peryer","sequence":"additional","affiliation":[{"name":"School of Health Sciences; University of East Anglia; Norwich UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Foschi","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Multiple Sclerosis Center - Neurology Unit, S.Maria delle Croci Hospital; AUSL Romagna; Ravenna Italy"},{"name":"Department of  Biotechnological and Applied Clinical Sciences; University of L'Aquila; L'Aquila Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Tramacere","sequence":"additional","affiliation":[{"name":"Department of Research and Clinical Development, Scientific Directorate; Fondazione IRCCS Istituto Neurologico Carlo Besta; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Baldin","sequence":"additional","affiliation":[{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna; Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Nonino","sequence":"additional","affiliation":[{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna; Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD015443.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/jnnp.2003.010090","article-title":"Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis","volume":"75","author":"Andersen","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0002|cit2","unstructured":"A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg\/Day or 1.5mg\/Day (Experimental Drug) as Compared to Placebo (ARPEGGIO) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02284568"},{"issue":"8","key":"10.1002\/14651858.CD015443.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"e1027","DOI":"10.1212\/WNL.0000000000010284","article-title":"A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis","volume":"95","author":"Giovannoni","year":"2020","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD015443.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1002\/14651858.CD015443.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1212\/wnl.41.4.533","article-title":"A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis","volume":"41","author":"Bornstein","year":"1991","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD015443.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/ane.13344","article-title":"Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial","volume":"143","author":"Cheshmavar","year":"2021","journal-title":"Acta Neurol Scand"},{"issue":"8","key":"10.1002\/14651858.CD015443.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1212\/wnl.39.8.1018","article-title":"A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis","volume":"39","author":"Ellison","year":"1989","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD015443.pub2-BIB0008|cit8","first-page":"484","article-title":"Cyclophosphamide Versus Rituximab in Progressive Forms of Multiple Sclerosis","volume":"57","author":"Etemadifar","year":"2020","journal-title":"Acta Med Iran"},{"issue":"9139","key":"10.1002\/14651858.CD015443.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(98)10039-9","article-title":"Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis","volume":"352","author":"European Study Group on interferon beta-1b in secondary progressive MS","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD015443.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1212\/WNL.0000000000011275","article-title":"Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses","volume":"96","author":"Benedict","year":"2021","journal-title":"Neurology"},{"issue":"10127","key":"10.1002\/14651858.CD015443.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD015443.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.410370108","article-title":"Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis","volume":"37","author":"Goodkin","year":"1995","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1002\/14651858.CD015443.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"issue":"9440","key":"10.1002\/14651858.CD015443.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(04)17101-8","article-title":"Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial","volume":"364","author":"Hommes","year":"2004","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD015443.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1212\/wnl.59.5.679","article-title":"Benefit of interferon beta-1a on MSFC progression in secondary progressive MS","volume":"59","author":"Cohen","year":"2002","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD015443.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"e614","DOI":"10.1212\/NXI.0000000000000614","article-title":"Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS","volume":"6","author":"Fox","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10023","key":"10.1002\/14651858.CD015443.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","article-title":"Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Lublin","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD015443.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/acn3.293","article-title":"Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis","volume":"3","author":"Komori","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"10.1002\/14651858.CD015443.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1212\/wnl.60.1.44","article-title":"Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial","volume":"60","author":"Leary","year":"2003","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD015443.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1177\/1352458509106937","article-title":"A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis","volume":"15","author":"Montalban","year":"2009","journal-title":"Mult Scler"},{"issue":"10","key":"10.1002\/14651858.CD015443.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1212\/01.wnl.0000146958.77317.3e.","article-title":"Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study","volume":"63","author":"Panitch","year":"2004","journal-title":"Neurology"},{"issue":"14","key":"10.1002\/14651858.CD015443.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1177\/1352458518808189","article-title":"Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial","volume":"24","author":"Fox","year":"2018","journal-title":"Mult Scler"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.msard.2019.01.044","article-title":"Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies","volume":"30","author":"Mayer","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1002\/14651858.CD015443.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1002\/14651858.CD015443.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/ana.25313","article-title":"Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial","volume":"84","author":"Wolinsky","year":"2018","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1002\/14651858.CD015443.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1177\/1352458507078400","article-title":"Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study","volume":"13","author":"P\u00f6hlau","year":"2007","journal-title":"Mult Scler"},{"issue":"1","key":"10.1002\/14651858.CD015443.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"e0168834","DOI":"10.1371\/journal.pone.0168834","article-title":"Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis","volume":"12","author":"Brochet","year":"2017","journal-title":"PLoS One"},{"issue":"11","key":"10.1002\/14651858.CD015443.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/WNL.56.11.1496","article-title":"Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results","volume":"56","author":"Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group","year":"2001","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD015443.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/ana.21079","article-title":"Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial","volume":"61","author":"Wolinsky","year":"2007","journal-title":"Ann Neurol"},{"issue":"8604","key":"10.1002\/14651858.CD015443.pub2-BIB0030|cit30","first-page":"179\u201383","article-title":"Double-masked trial of azathioprine in multiple sclerosis","volume":"2","author":"Dutch","year":"1988","journal-title":"Lancet"},{"issue":"8739","key":"10.1002\/14651858.CD015443.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0140-6736(91)93389-Q","article-title":"The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis","volume":"337","year":"1991","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD015443.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"112\u20138","DOI":"10.1136\/jnnp.62.2.112","article-title":"Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria","volume":"62","author":"Edan","year":"1997","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"10. Vyp. 2","key":"10.1002\/14651858.CD015443.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.17116\/jnevro201911910110","article-title":"The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis","volume":"119","author":"Evdoshenko","year":"2019","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"issue":"14","key":"10.1002\/14651858.CD015443.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1177\/1352458518808189","article-title":"Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial","volume":"24","author":"Fox","year":"2018","journal-title":"Mult Scler"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0035|cit35","volume-title":"Recent Advances in Multiple Sclerosis Therapy","author":"Ghezzi","year":"1989"},{"issue":"9350","key":"10.1002\/14651858.CD015443.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD015443.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/1352458515594440","article-title":"A 10-year follow-up of the European multicenter trial of interferon \u03b2-1b in secondary-progressive multiple sclerosis","volume":"22","author":"Kuhle","year":"2016","journal-title":"Mult Scler"},{"issue":"5","key":"10.1002\/14651858.CD015443.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF00838165","article-title":"A double blind study on azathioprine efficacy in multiple sclerosis: final report","volume":"240","author":"Milanese","year":"1993","journal-title":"Journal of Neurology"},{"issue":"7169","key":"10.1002\/14651858.CD015443.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(61)91308-3","article-title":"Multiple sclerosis. Trials of maintenance treatment with prednisolone and soluble aspirin","volume":"1","author":"Miller","year":"1961","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD015443.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/ana.25313","article-title":"Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial","volume":"84","author":"Wolinsky","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0041|cit41","unstructured":"EUCTR2012-003056-36 https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2012-003056-36"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0042|cit42","unstructured":"A safety and efficacy study of BG00012 in slowing the progression of disability in patients with Secondary Progressive Multiple Sclerosis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2014%E2%80%90003021%E2%80%9018%E2%80%90PL"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0043|cit43","unstructured":"A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2018%E2%80%90001511%E2%80%9073%E2%80%90ES"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0044|cit44","unstructured":"A phase IIIb multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ocrelizumab in adults with primary progressive multiple sclerosis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2018-001511-73"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0045|cit45","unstructured":"A phase 2b study of Cladribine to halt deterioration in people with advanced multiple sclerosis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2018%E2%80%90005038%E2%80%9039%E2%80%90GB"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0046|cit46","unstructured":"Non-inferiority study of ocrelizumab and rituximab in active multiple sclerosis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2020%E2%80%90002981%E2%80%9015%E2%80%90DK"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0047|cit47","unstructured":"Comparison of effectiveness and complication of rituximab and fingolimod in improvement disability motion https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=IRCT20130812014333N125"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0048|cit48","unstructured":"A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis https:\/\/clinicaltrials.gov\/study\/NCT04035005"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0049|cit49","unstructured":"Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04688788"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0050|cit50","unstructured":"ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis (ChariotMS) https:\/\/clinicaltrials.gov\/show\/NCT04695080"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaut.2014.05.005","article-title":"Immunomodulation neuroprotection and remyelination. The fundamental therapeutic effects of glatiramer acetate: a critical review","volume":"54","author":"Aharoni","year":"2014","journal-title":"Journal of Autoimmunity"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"i2016","DOI":"10.1136\/bmj.i2016","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD015443.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/1756285609344375","article-title":"Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms","volume":"2","author":"Awad","year":"2009","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"5","key":"10.1002\/14651858.CD015443.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/1352458517690821","article-title":"Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis","volume":"23","author":"Benedict","year":"2017","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"issue":"4","key":"10.1002\/14651858.CD015443.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/ane.12963","article-title":"Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - outlier or predecessor?","volume":"138","author":"Berntsson","year":"2018","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"661882","DOI":"10.3389\/fimmu.2021.661882","article-title":"Rituximab in multiple sclerosis: are we ready for regulatory approval?","volume":"12","author":"Brancati","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Brennan","year":"2020","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1093\/brain\/aws246","article-title":"Cortical lesion load associates with progression of disability in multiple sclerosis","volume":"135","author":"Calabrese","year":"2012","journal-title":"Brain"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1177\/13524585221094944","article-title":"Is the effect of drugs in progressive MS only due to an effect on inflammation? A subgroup meta-analysis of randomised trials","volume":"28","author":"Capanna","year":"2022","journal-title":"Mult Scler"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/1472-6963-14-286","article-title":"Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data","volume":"14","author":"Carroll","year":"2014","journal-title":"BMC Health Services Research"},{"issue":"10","key":"10.1002\/14651858.CD015443.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLOS One"},{"issue":"12","key":"10.1002\/14651858.CD015443.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1212\/WNL.0b013e318288694e","article-title":"International Pediatric MS Study Group Clinical Trials Summit: meeting report","volume":"80","author":"Chitnis","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD015443.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clinical Neuropharmacology"},{"issue":"1","key":"10.1002\/14651858.CD015443.pub2-BIB0065|cit65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006264.pub2","article-title":"Corticosteroids for the long-term treatment in multiple sclerosis","author":"Ciccone","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD015443.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"9313","key":"10.1002\/14651858.CD015443.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","article-title":"Multiple sclerosis","volume":"359","author":"Compston","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/brain\/awh714","article-title":"Age at disability milestones in multiple sclerosis","volume":"129","author":"Confavreux","year":"2006","journal-title":"Brain"},{"issue":"8","key":"10.1002\/14651858.CD015443.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jclinepi.2013.03.009","article-title":"Combining follow-up and change data is valid in meta-analyses of continuous outcomes: a meta-epidemiological study","volume":"66","author":"da Costa","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD015443.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"3","key":"10.1002\/14651858.CD015443.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/WCO.0000000000000094","article-title":"Relapsing and progressive forms of multiple sclerosis: insights from pathology","volume":"27","author":"Dutta","year":"2014","journal-title":"Current Opinion in Neurology"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0072|cit72","unstructured":"European Medicines Agency Nerventra www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nerventra"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0073|cit73","unstructured":"European Medicines Agency Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis www.ema.europa.eu\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-multiple-sclerosis_en-0.pdf"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0074|cit74","unstructured":"European Medicines Agency Mavenclad www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mavenclad"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0075|cit75","unstructured":"European Medicines Agency EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta www.ema.europa.eu\/en\/news\/ema-recommends-immediate-suspension-recall-multiple-sclerosis-medicine-zinbryta"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0076|cit76","unstructured":"European Medicines Agency Ocrevus www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ocrevus"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0077|cit77","unstructured":"European Medicines Agency Mayzent www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mayzent"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0078|cit78","unstructured":"European Medicines Agency Zeposia www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zeposia"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0079|cit79","unstructured":"European Medicines Agency Ponvory www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ponvory"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0080|cit80","unstructured":"European Medicines Agency Vumerity www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vumerity"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0081|cit81","unstructured":"European Medicines Agency Kesimpta www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kesimpta"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0082|cit82","unstructured":"FDA approves new drug to treat multiple sclerosis www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treat-multiple-sclerosis"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0083|cit83","unstructured":"FDA working with manufacturers to withdraw Zinbryta from the market in the United States www.fda.gov\/drugs\/drug-safety-and-availability\/fda-working-manufacturers-withdraw-zinbryta-market-united-states"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0084|cit84","unstructured":"FDA approves new oral treatment for multiple sclerosis www.fda.gov\/news-events\/press-announcements\/fda-approves-new-oral-treatment-multiple-sclerosis"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0085|cit85","unstructured":"FDA approves new oral drug to treat multiple sclerosis www.fda.gov\/news-events\/press-announcements\/fda-approves-new-oral-drug-treat-multiple-sclerosis"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0086|cit86","unstructured":"Novel drug approvals for 2020 www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/novel-drug-approvals-2020"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0087|cit87","unstructured":"Novel Drug Approvals for 2021 www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/novel-drug-approvals-2021"},{"issue":"6","key":"10.1002\/14651858.CD015443.pub2-BIB0088|cit88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008933.pub2","article-title":"Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis","author":"Filippini","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0089|cit89","first-page":"15","article-title":"Mechanism of action of mitoxantrone","volume":"12","author":"Fox","year":"2004","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"GBD 2016 Multiple Sclerosis Collaborators","year":"2019","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1002\/14651858.CD015443.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40120-018-0112-1","article-title":"European and American guidelines for multiple sclerosis treatment","volume":"7","author":"Ghezzi","year":"2018","journal-title":"Neurology and Therapy"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"175628642110667","DOI":"10.1177\/17562864211066751","article-title":"Smouldering multiple sclerosis: the 'real MS'","volume":"15","author":"Giovannoni","year":"2022","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0093|cit93","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2023"},{"issue":"2","key":"10.1002\/14651858.CD015443.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2466\/pms.1977.44.2.367","article-title":"Paced auditory serial-addition task: a measure of recovery from concussion","volume":"44","author":"Gronwall","year":"1977","journal-title":"Perceptual and Motor Skills"},{"issue":"12","key":"10.1002\/14651858.CD015443.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"GRADE guidelines: 8. Rating the quality of evidence - indirectness","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD015443.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"American Journal of Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD015443.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical Research Edition)"},{"issue":"2","key":"10.1002\/14651858.CD015443.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0099|cit99","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0100|cit100","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0101|cit101","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"issue":"6","key":"10.1002\/14651858.CD015443.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1177\/0091270011407068","article-title":"A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology","volume":"52","author":"Hu","year":"2012","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jclinepi.2017.05.006","article-title":"The GRADE Working Group clarifies the construct of certainty of evidence","volume":"87","author":"Hultcrantz","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"issue":"9805","key":"10.1002\/14651858.CD015443.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD015443.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11591110-000000000-00000","article-title":"The mechanism of action of interferon-\u03b2 in relapsing multiple sclerosis","volume":"25","author":"Kieseier","year":"2011","journal-title":"CNS Drugs"},{"issue":"11","key":"10.1002\/14651858.CD015443.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"11","key":"10.1002\/14651858.CD015443.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","article-title":"Progressive multiple sclerosis: pathology and pathogenesis","volume":"8","author":"Lassmann","year":"2012","journal-title":"Nature Reviews. Neurology"},{"issue":"9","key":"10.1002\/14651858.CD015443.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1177\/13524585211030207","article-title":"Ethical use of off-label disease-modifying therapies for multiple sclerosis","volume":"27","author":"Laurson-Doube","year":"2021","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"issue":"1","key":"10.1002\/14651858.CD015443.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clinical Neuropharmacology"},{"issue":"3","key":"10.1002\/14651858.CD015443.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/brain\/awq386","article-title":"Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway","volume":"134","author":"Linker","year":"2011","journal-title":"Brain"},{"issue":"3","key":"10.1002\/14651858.CD015443.pub2-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/wnl.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD015443.pub2-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.11124\/JBISRIR-D-19-00178","article-title":"Outcome measures for disease-modifying therapies in relapsing multiple sclerosis randomized clinical trials: a scoping review protocol","volume":"18","author":"Lucchetta","year":"2020","journal-title":"JBI Evidence Synthesis"},{"issue":"6","key":"10.1002\/14651858.CD015443.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/1756285615605429","article-title":"Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes","volume":"8","author":"Lycke","year":"2015","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"3","key":"10.1002\/14651858.CD015443.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0303-8467(02)00035-5","article-title":"Compartmentalization of the immune response in the central nervous system and natural history of multiple sclerosis. Implications for therapy","volume":"104","author":"Massacesi","year":"2002","journal-title":"Clinical Neurology and Neurosurgery"},{"issue":"1","key":"10.1002\/14651858.CD015443.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Annals of Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD015443.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jns.2008.06.032","article-title":"Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis","volume":"274","author":"Meinl","year":"2008","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1471-2377-14-58","article-title":"Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis","volume":"14","author":"Meyer-Moock","year":"2014","journal-title":"BMC Neurology"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0118|cit118","unstructured":"Microsoft Excel Microsoft Corporation 2024"},{"issue":"1","key":"10.1002\/14651858.CD015443.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"154","DOI":"10.7150\/thno\/v01p0154","article-title":"Integrin targeted therapeutics","volume":"17","author":"Millard","year":"2011","journal-title":"Theranostics"},{"issue":"3","key":"10.1002\/14651858.CD015443.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"e053246","DOI":"10.1136\/bmjopen-2021-053246","article-title":"Defining decision thresholds for judgments on health benefits and harms using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Evidence to Decision (EtD) frameworks: a protocol for a randomised methodological study (GRADE-THRESHOLD)","volume":"12","author":"Morgano","year":"2022","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0121|cit121","first-page":"177","article-title":"An update of teriflunomide for treatment of multiple sclerosis","volume":"9","author":"Oh","year":"2013","journal-title":"Therapeutics and Clinical Risk Management"},{"issue":"10","key":"10.1002\/14651858.CD015443.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry","volume":"61","author":"Peters","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0123|cit123","first-page":"g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ (Clinical Research Edition)"},{"issue":"9","key":"10.1002\/14651858.CD015443.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/1352458507078400","article-title":"Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study","volume":"13","author":"P\u00f6hlau","year":"2007","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"issue":"2","key":"10.1002\/14651858.CD015443.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0126|cit126","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"issue":"1","key":"10.1002\/14651858.CD015443.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jclinepi.2014.08.012","article-title":"Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data","volume":"68","author":"Rhodes","year":"2015","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0128|cit128","unstructured":"Daniels K Frequin S van der Wees PJ van de Garde EM Biesma DH Development of the international, multidisciplinary, patient-relevant standard outcome set for Multiple Sclerosis: the S.O.S.MS project spem.pt\/wp-content\/uploads\/2021\/03\/S.O.S.MS_ACTRIMS_KDaniels_18-12-2020-2.pdf"},{"issue":"2","key":"10.1002\/14651858.CD015443.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD015443.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0131|cit131","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from gdt.gradepro.org\/app\/handbook\/handbook.html"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jclinepi.2022.07.015","article-title":"GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions","volume":"150","author":"Sch\u00fcnemann","year":"2022","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/ane.13697","article-title":"Is there a role for off-label high-efficacy disease-modifying drugs in progressive multiple sclerosis? A network meta-analysis","volume":"146","author":"Silva","year":"2022","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"10.1002\/14651858.CD015443.pub2-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000109932","article-title":"Intravenous polyclonal human immunoglobulins in multiple sclerosis","volume":"5","author":"Soelberg Sorensen","year":"2008","journal-title":"Neurodegenerative Diseases"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0135|cit135","unstructured":"Stata StataCorp 2024"},{"issue":"9","key":"10.1002\/14651858.CD015443.pub2-BIB0136|cit136","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011381.pub2","article-title":"Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis","author":"Tramacere","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD015443.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews","volume":"41","author":"Turner","year":"2012","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD015443.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ije\/dys222","article-title":"Evaluation of inconsistency in networks of interventions","volume":"42","author":"Veroniki","year":"2013","journal-title":"International Journal of Epidemiology"},{"issue":"14","key":"10.1002\/14651858.CD015443.pub2-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"1","key":"10.1002\/14651858.CD015443.pub2-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/135245859500100107","article-title":"Outcomes assessment in multiple sclerosis clinical trials: a critical analysis","volume":"1","author":"Whitaker","year":"1995","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"issue":"2","key":"10.1002\/14651858.CD015443.pub2-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/1536867X1101100206","article-title":"Multivariate random-effects meta-regression: updates to mvmeta","volume":"11","author":"White","year":"2011","journal-title":"Stata Journal"},{"key":"10.1002\/14651858.CD015443.pub2-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.04.018","article-title":"Development of the summary of findings table for network meta-analysis","volume":"115","author":"Yepes-Nu\u00f1ez","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD015443.pub2-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"205521731984846","DOI":"10.1177\/2055217319848466","article-title":"Treatment of multiple sclerosis in special populations: the case of refugees","volume":"6","author":"Zeineddine","year":"2020","journal-title":"Multiple Sclerosis Journal - Experimental, Translational and Clinical"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T06:03:07Z","timestamp":1762754587000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015443.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":143,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015443.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]}}}